Neurointerventional Section, Department of Radiology, Hacettepe University Hospital, Sihhiye, Ankara, Turkey.
AJNR Am J Neuroradiol. 2012 Sep;33(8):1436-46. doi: 10.3174/ajnr.A3246. Epub 2012 Jul 19.
Flow-diverting devices now offer a new treatment alternative for cerebral aneurysms. We present the results of a large single-center series of patients treated with the PED, including long-term follow-up.
Between November 2008 and September 2011, sidewall aneurysms with a wide neck (≥4 mm) or unfavorable dome-neck ratio (≤1.5); large/giant, fusiform, dissecting, blister-like, and recurrent sidewall aneurysms; aneurysms at difficult angles; and aneurysms in which a branch was originating directly from the sac were treated with the PED. Patients were premedicated with dual antiplatelet medications. Data, including demographics, aneurysm features, clinical presentation, complications, results, and follow-up information, for up to 2 years are presented.
Two hundred fifty-one aneurysms in 191 patients were treated. Of these, 96 (38.3%) were large or giant (≥10 mm). In 34/251 (13.5%), PEDs were used for retreatment. Adjunctive coiling was performed in 11 aneurysms (2.1%). The mean number of devices per aneurysm was 1.3. One aneurysm ruptured in the fourth month posttreatment (0.5%), and symptomatic in-construct stenosis was detected in 1 patient (0.5%) treated with percutaneous transarterial angioplasty. Any event rate was 27/191 (14.1%), with a permanent morbidity of 1% and mortality of 0.5%. Control angiography was available in 182 (95.3%) patients with 239 (95.2%) aneurysms. In 121 aneurysms (48.2%), 1- to 2-year control angiography was available. The aneurysm occlusion rate was 91.2% in 6 months, increasing to 94.6%.
Use of the PED is safe, efficacious, and durable in cerebral aneurysm treatment, with low morbidity-mortality and high occlusion rates as confirmed with mid- to long-term control angiography.
血流导向装置为颅内动脉瘤提供了一种新的治疗选择。我们呈现了一组大型单中心系列患者的治疗结果,包括长期随访。
在 2008 年 11 月至 2011 年 9 月期间,采用血流导向装置(PED)治疗宽颈(≥4mm)或不利的瘤颈比(≤1.5)的侧壁动脉瘤;大型/巨型、梭形、夹层、疱状和复发性侧壁动脉瘤;在困难角度的动脉瘤;以及起源于瘤囊的分支直接起源的动脉瘤。患者预先接受双联抗血小板药物治疗。我们呈现了多达 2 年的患者数据,包括人口统计学、动脉瘤特征、临床表现、并发症、结果和随访信息。
191 例患者中的 251 个动脉瘤接受了治疗。其中,96 个(38.3%)为大型或巨型(≥10mm)。在 251 个动脉瘤中有 34 个(13.5%)进行了再治疗,11 个(2.1%)进行了辅助线圈栓塞。每个动脉瘤平均使用 1.3 个装置。1 个动脉瘤在治疗后第 4 个月破裂(0.5%),1 例经皮经动脉血管成形术治疗的患者出现症状性吻合口狭窄(0.5%)。任何事件发生率为 27/191(14.1%),永久性发病率为 1%,死亡率为 0.5%。182 例(95.3%)患者进行了控制性血管造影,其中 239 个(95.2%)动脉瘤有控制性血管造影。在 121 个动脉瘤(48.2%)中,有 1 至 2 年的控制性血管造影。6 个月时的动脉瘤闭塞率为 91.2%,增加至 94.6%。
在颅内动脉瘤治疗中,使用血流导向装置是安全、有效且持久的,中期至长期的控制性血管造影证实了其发病率-死亡率低,闭塞率高。